Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy

In Italy, the use of SAP with automated insulin suspension is associated with projected improvements in outcomes as compared to CSII. These benefits translate into an ICER usually considered as good value for money, particularly in patients at elevated risk of hypoglycemia.